

**2026 BIOMARKERS CONFERENCE AGENDA**

**PROCEEDING TOWARDS THE ESTABLISHMENT OF A NATIONAL STRATEGY FOR ADVANCING CGP IN METASTATIC CANCER CARE:  
ALIGNING PATIENT, CLINICAL, AND POLICY PERSPECTIVES**

**TARGET AUDIENCE: Oncology Professionals, Pathologists, Patients and Caregivers, Advocates, Researchers, Policy Professionals, Industry**  
**Goals: Education, Awareness, Advocacy**

**Steering Committee: Dr. Monika Krzyzanowska (Co-Chair), Dr. Shantanu Banerjee (Co-Chair),  
Dr. Mita Manna, Dr. Doha Itani, Don Husereau, Matthew Brougham, Dr. Georgia Balsevich, Katie Hulan**

**DAY 1: JUNE 18, 2026**

**LAYING THE FOUNDATION FOR THE ESTABLISHMENT OF A NATIONAL STRATEGY FOR CGP READINESS**

| Time                  | Session Title & Descriptions   | Presenters/Speakers   |
|-----------------------|--|---|
| 9:30 a.m. – 9:45 a.m. | <p><b>Conference Day 1 Opening</b></p> <p>CCRAN is a national, patient-focused advocacy group, dedicated to improving the longevity and quality of life for all cancer patients in Canada through their persistent efforts in support, education, and advocacy through equal and timely access to effective therapies.</p> <p>Our fourth annual pan-tumour Biomarkers Conference will build on the outcomes of past conferences. Over the course of two days, we will once again engage clinicians, pathologists, researchers, policy professionals, patients, and caregivers from within and outside Canada. Building on this foundation, the program will emphasize cross-sector dialogue to advance a more coordinated, pan-Canadian approach to comprehensive genomic profiling in metastatic cancer care. The discussions will explore how patient, clinical, and policy perspectives can be better aligned to support sustainable system-level progress.</p> | <p><u>Conference Moderator:</u><br/><b>Cassandra Macaulay, B.Sc., MHS, RTNM</b><br/>Chief Research Officer, CCRAN</p> |

|                                |  |   |
|--------------------------------|--|---|
| <p>9:45 a.m. – 10:00 a.m.</p>  | <p><b>Welcome from CCRAN’s President &amp; CEO</b></p> <p>A warm welcome and sincere thanks to all experts and participants. Key highlights in this session include:</p> <ul style="list-style-type: none"> <li>• A patient perspective, sharing their cancer journey</li> <li>• Exploring patient insights in advancing meaningful cancer care</li> </ul>   | <p><b>Filomena Servidio-Italiano, Hon B.Sc., B.Ed., M.A.</b><br/>President &amp; CEO, CCRAN</p> <p><i>Patient Perspective</i><br/><b>Gary Puppa</b><br/>Stage IV Colon Cancer Patient</p>                             |
| <p>10:00 a.m. – 10:30 a.m.</p> | <p><b>Key Learnings from CCRAN’s 2025 Biomarkers Conference</b></p> <p>The objectives and outcomes of CCRAN’s 2025 Biomarkers Conference have been captured and summarized in a publication in Current Oncology.</p> <p>The lead author of the publication will present the key findings, themes and calls to action as highlighted in the paper.</p>  | <p><i>Presentation</i><br/><b>Dr. Stephanie Snow, MD, FRCPC</b><br/>Medical Oncologist, QEII Health Sciences Centre;<br/>Professor, Dalhousie University</p>  |
| <p>10:30 a.m. – 11:45 a.m.</p> | <p><b>Economic and Health System Readiness: Leveraging Evidence to Support Comprehensive Genomic Profiling Integration Across Canada</b></p> <p>To build a sustainable and equitable precision oncology framework, stakeholders require both a compelling economic case and a clear understanding of health system readiness for routine genome-based testing. This presentation draws on two complementary bodies of work, the <a href="#">comprehensive genomic profiling (CGP) cost and benefit analysis findings</a> and the <a href="#">State of Readiness Progress Report II</a>, which examines the conditions required to support the routine use of genomic testing across Canada. Together, these perspectives will highlight jurisdictional progress, persistent system gaps, and the role of real-world evidence to inform coordinated decision-making. The session will support a broader national conversation on how economic evidence and readiness assessment can guide CGP planning and alignment across provinces and sectors.</p> <p>This presentation will focus on:</p> <ul style="list-style-type: none"> <li>• Assessing current system readiness for routine genomic testing, including progress and persistent challenges across jurisdictions</li> <li>• Examining economic evidence for CGP and what it means for real-world funding and system decision-making</li> </ul> | <p><i>Keynote Presentation</i><br/><b>Don Husereau, B.Sc. Pharm, M.Sc.</b><br/>Adjunct Professor of Medicine, University of Ottawa</p> <p><b>Eddy Nason, MPhil, B.Sc.</b><br/>Director, Health, Signal49 Research</p> |

|                         |  |   |
|-------------------------|--|---|
|                         | <ul style="list-style-type: none"> <li>Identifying practical opportunities to advance coordinated, pan-Canadian CGP implementation</li> </ul>  |   |
| 11:45 a.m. – 12:30 p.m. | <p><b>Health Break</b></p> <p><b>Educational Videos</b></p> <p><b>Virtual Networking Room Hosted by Merck (11:45 a.m. - 12:15 p.m.)</b><br/> Moderated by: Don Wood, Community &amp; Patient Engagement Specialist, CCRAN<br/> Merck Lead: Constance Planchet, Diagnostic Commercial Lead, Precision Medicine, Oncology, Merck</p>   |   |
| 12:30 p.m. – 1:00 p.m.  | <p><b>CDA’s Framework for Equitable Biomarker Access: Key Recommendations and Future Directions</b></p> <p>The Canada’s Drug Agency (CDA)–AMC Biomarker Assessment Framework represents a critical step toward improving equitable access to biomarker testing across Canada. This presentation will introduce the purpose and structure of the Framework, highlighting its potential to guide more consistent, evidence-informed decision-making and system-wide coordination. Attendees will hear from CDA about the Framework’s objectives, including short- and medium-term strategies to support implementation and collaboration across jurisdictions. The discussion will also highlight opportunities for shared infrastructure, coordinated data access, and policy levers to enable broader uptake.</p> <p>Session objectives:</p> <ul style="list-style-type: none"> <li>Introduce the CDA-AMC Biomarker Assessment Framework and its purpose in supporting equitable biomarker testing decision-making across Canada</li> <li>Outline implementation timelines, early priorities, and mechanisms for interprovincial collaboration</li> <li>Highlight opportunities for alignment and collaboration across provinces and sectors to enable shared infrastructure, data access, and assessment processes</li> </ul> | <p><u>Presentation</u><br/> <b>Dr. Laura Weeks, Ph.D.</b><br/> Director, Health Technology Assessment, Canada’s Drug Agency</p> |
| 1:00 p.m. – 2:00 p.m.   | <p><b>Stakeholder Reflections on CDA’s National Biomarker Assessment Framework: A Cross-Sector Dialogue</b></p> <p>Following the presentation of the CDA Biomarker Assessment Framework, this multi-stakeholder panel will examine its practical implications and translational potential across jurisdictions. Panelists from clinical, regulatory, policy, and patient advocacy sectors will share diverse perspectives on the Framework’s relevance, anticipated challenges, and opportunities for cross-sector alignment. The</p>  | <p><u>Moderator</u><br/> <b>William Dempster</b><br/> President, 3Sixty Public Affairs</p>                                      |

|                       |  |   |
|-----------------------|--|---|
|                       | <p>discussion will explore how a truly national approach to biomarker testing can be equitably implemented and sustainably scaled, with a focus on shared infrastructure, governance mechanisms, and meaningful integration of patient voice.</p> <p>Key objectives to be explored:</p> <ul style="list-style-type: none"> <li>• Reflect on the CDA Biomarker Assessment Framework through clinical, policy, regulatory, and patient lenses</li> <li>• Explore opportunities to strengthen national alignment and equitable access to biomarker testing across Canada</li> <li>• Discuss what is needed to support transparent and coordinated implementation of the Framework as Canada advances biomarker testing across jurisdictions</li> </ul>  | <p><u>Patient Perspective</u></p> <p><b>Dr. Catalina Lopez-Correa, MD, Ph.D.</b><br/>Breast Cancer Survivor and Advocate; Co-Chair, Global Genomics Network for Education and Training (GGNET); Co-Chair, Patient Working Group, Marathon of Hope Cancer Centres Network</p> <p><u>Panelists</u></p> <p><b>Cassandra Macaulay, B.Sc., MHS, RTNM</b><br/>Chief Research Officer, CCRAN</p> <p><b>Dr. Laura Weeks, Ph.D.</b><br/>Director, Health Technology Assessment, Canada’s Drug Agency</p> <p><b>Dr. Sharlene Gill, MD, MPH, MBA, FASCO</b><br/>Professor of Medicine, UBC; Medical Oncologist, BC Cancer - Vancouver; Medical &amp; Scientific Advisory Board Co-Chair, Colorectal Cancer Resource &amp; Action Network (CCRAN)</p> <p><b>Laura Greer</b><br/>Patient Expert; Executive Vice President and Global Client Lead, Health &amp; Wellness, Burson Canada; Breast Cancer Advocate</p> |
| 2:00 p.m. – 3:00 p.m. | <p><b>The Patient Voice Amplified: CGP Making a Difference in the Canadian Cancer Care Landscape Across Tumour Types</b></p> <p>As Canada considers broader implementation of comprehensive genomic profiling (CGP) in metastatic cancer care, patients remain a critical source of real-world insight. This session brings forward the voices of patients across tumour types who have directly benefited from CGP. Patients discuss the impact CGP had on treatment decision-making and overall patient experience. They also share perspectives on access to CGP, including how availability, timing, and integration into care shaped treatment options, communication with care teams, and their experience of living with advanced cancer. As system-level planning advances, these perspectives underscore the importance</p> | <p><u>Moderator</u></p> <p><b>Eva Villalba, MBA, M.Sc.</b><br/>VBHC Green Belt; Executive Director, Quebec Cancer Coalition; President, VBHC Learning Community</p> <p><u>Patient Panel</u></p> <p><b>Corri Desaulniers</b><br/>Stage IV Cholangiocarcinoma Patient, FGFR2 Fusion; Patient Partner &amp; Advocate, Canadian Cholangiocarcinoma Collaborative (C3)</p>   |

|                       |   |  |
|-----------------------|---|--|
|                       | <p>of timely and equitable access, consistent integration, and clear communication across the diagnostic and treatment continuum.</p> <p>Areas of focus:</p> <ul style="list-style-type: none"> <li>• Illustrate how molecular testing, including CGP, has influenced treatment decisions and patient outcomes across tumour types</li> <li>• Explore patient perspectives on access to testing, including gaps in availability, geography, timing, and integration into care</li> <li>• Examine how communication, shared decision-making, and patient experience can inform policy, clinical practice, and health system planning</li> </ul>  | <p><b>Mariana Markovic, RN, MN, MHSC, CHE</b><br/>Stage IV Colon Cancer Survivor; Healthcare Consultant, Independent Healthcare Consulting Inc.; Patient Advocate</p> <p><b>Laura Greer</b><br/>State IV Breast Cancer Survivor &amp; Advocate; Patient Expert; Executive Vice President and Global Client Lead, Health &amp; Wellness, Burson Canada</p> <p><b>Dr. Mary K. Bryson, Ph.D.</b><br/>Stage IV EGFR Lung Cancer Patient; International Association for the Study of Lung Cancer (IASLC) STARS Scholar Patient Advocate; Professor, Department of Language and Literacy Education (LLED), Faculty of Education, The University of British Columbia</p> <p><b>Brad Sluiter</b><br/>Stage IV Pancreatic Cancer Survivor</p> |
| 3:00 p.m. – 3:15 p.m. | <p><b>Health Break</b></p> <p><b>Educational Videos</b></p>   |  |
| 3:15 p.m. – 4:45 p.m. | <p><b>Molecular Tumour Boards in Practice: Advancing Standardization and System Readiness</b></p> <p>Molecular Tumour Boards (MTBs) play a pivotal role in translating complex genomic and molecular testing results into clinical decision-making. As the use of comprehensive genomic profiling (CGP) and other advanced molecular diagnostics expands across Canada, MTBs are increasingly central to ensuring consistent interpretation and equitable access to precision oncology expertise.</p> <p>Yet MTB structure, availability, and functionality vary widely across jurisdictions. This session will examine how MTBs contribute to standardizing interpretation of CGP and other advanced diagnostic approaches, while exploring emerging models that promote equity, consistency, and scalability. As molecular testing becomes more complex, the discussion will also consider the importance of clinician education and ongoing knowledge support in strengthening genomics literacy and</p> | <p><i>Moderator</i></p> <p><b>Dr. Michael Raphael, MD, FRCPC</b><br/>Medical Oncologist, Early Age Onset CRC Cancer Clinic Lead, Odette Cancer Centre, Sunnybrook Health Sciences Centre; Co-Chair, Medical &amp; Scientific Advisory Board, CCRAN</p> <p><i>Caregiver Perspective</i></p> <p><b>Jennifer Willis</b><br/>Caregiver to spouse diagnosed with Stage IIIC Cholangiocarcinoma</p>  |

|                              |   |  |
|------------------------------|---|--|
|                              | <p>enabling effective interpretation of increasingly detailed molecular reports, particularly in settings where formal MTB infrastructure may be limited.<br/>Key topics of discussion include:</p> <ul style="list-style-type: none"> <li>• The evolving role of MTBs in standardizing CGP interpretation and other advanced molecular diagnostics, supporting consistent clinical decision-making</li> <li>• Interprovincial variation in MTB models, including emerging collaborative practices and jurisdictions where formalized MTBs are not yet established</li> <li>• Persistent challenges to MTB integration across jurisdictions, including limited resourcing, variable clinical engagement, and data-sharing barriers</li> <li>• The importance of clinician education and knowledge sharing to support interpretation of complex molecular reports</li> </ul>   | <p><u>Panelist</u><br/><b>Dr. Alan Spatz, MD, M.Sc.</b><br/>Professor, Departments of Pathology &amp; Oncology, McGill University; Chief, Department of Clinical Laboratory Medicine, MUHC; Medical Director, Optilab Montreal-MUHC Network</p> <p><b>Prof. Arndt Vogel, MD, Ph.D.</b><br/>Clinician Scientist, Division of Gastroenterology and Hepatology, Toronto General Hospital &amp; Medical Oncology, Princess Margaret Cancer Centre; Professor of Medicine, University of Toronto</p> <p><b>Dr. Erin DeBruin</b><br/>Manager, Professional Education and Implementation, Genome BC</p> <p><b>Dr. Shantanu Banerji, B.Sc. (Med), MD, FRCPC</b><br/>Co-Chair, Expert Steering Committee; Director of Precision Oncology and Advanced Therapeutics, CancerCare Manitoba</p> |
| <p>4:45 p.m. – 5:45 p.m.</p> | <p><b>Driving Access Through Partnership: The Role of Industry in Canada’s Precision Oncology Landscape</b></p> <p>As Canada advances toward more coordinated and equitable access to comprehensive genomic profiling (CGP), industry partners play an important role in helping address longstanding barriers related to infrastructure, education, turnaround times, and system capacity. This session will explore how thoughtful and transparent collaboration across public and private stakeholders can help strengthen CGP readiness across provinces while supporting a patient-centred and evidence-informed approach to precision oncology.</p> <p>Through a national panel discussion, experts will examine opportunities to align industry innovation with oncology system priorities, enhance cross-sector coordination, and contribute to sustainable models that support equitable access to CGP across Canada. The discussion will also explore how</p> | <p><u>Moderator</u><br/><b>Dr. Georgia Balsevich, Ph.D.</b><br/>Senior Sector Innovation Manager, Genome Alberta</p> <p><u>Caregiver Perspective</u><br/><b>Don Wood</b><br/>Caregiver to spouse who succumbed to Stage IV Colorectal Cancer; Community &amp; Patient Engagement Specialist, CCRAN</p>   |

|                       |  |  |
|-----------------------|--|--|
|                       | <p>industry and health system partners can collaborate to navigate operational realities and foster sustainable partnerships that advance CGP across jurisdictions.</p> <p>This session will explore:</p> <ul style="list-style-type: none"> <li>• How industry partners can support the advancement of CGP within Canada’s evolving precision oncology landscape</li> <li>• Opportunities for collaboration across industry, policy, clinical, and patient communities to support coordinated approaches to CGP</li> <li>• Considerations for fostering responsible and sustainable partnerships that align innovation with health system priorities and patient needs</li> </ul> | <p><i>Industry Panel</i></p> <p><b>Dr. André Galarneau, M.Sc., Ph.D.</b><br/>Executive Director &amp; Vice-President, Oncology Business Unit, Merck Canada Inc.</p> <p><b>Paul Krzyzanowski</b><br/>Medical Director, Precision Medicine, Johnson &amp; Johnson</p> <p><b>Mark Oatway</b><br/>Head, Diagnostics and Transforming Care, Oncology, AstraZeneca Canada</p> <p><i>Additional experts to be confirmed</i></p> |
| 5:45 p.m. – 5:50 p.m. | <b>Glance at Day 2. Closing Remarks from CCRAN’s President &amp; CEO.</b>  | <b>Filomena Servidio-Italiano, Hon B.Sc., B.Ed., M.A.</b><br>President & CEO, CCRAN  |

| <p><b>2026 BIOMARKERS CONFERENCE AGENDA</b></p> <p><b>PROCEEDING TOWARDS THE ESTABLISHMENT OF A NATIONAL STRATEGY FOR ADVANCING CGP IN METASTATIC CANCER CARE:<br/>ALIGNING PATIENT, CLINICAL, AND POLICY PERSPECTIVES</b></p> |   |  |
|--|---|--|
| <p><b>DAY 2: JUNE 19, 2026</b></p> <p><b>ADVANCING THE VISION: LEVERAGING CLINICAL EVIDENCE AND THE PATIENT VOICE</b></p>  |   |  |
| Time   | Session Title & Descriptions  | Expert Speakers  |
| 9:30 a.m. – 9:40 a.m.  | <p><b>Conference Day 2 Opening</b></p> <p>A brief recap of sessions from day one:</p> <ul style="list-style-type: none"> <li>• Key take-aways from presentations and panel discussions</li> <li>• Conference objectives, day 2</li> </ul> | <p><i>Conference Moderator:</i></p> <p><b>Cassandra Macaulay, B.Sc., MHS, RTNM</b><br/>Chief Research Officer, CCRAN</p> |

|                                |  |   |
|--------------------------------|--|---|
| <p>9:40 a.m. – 10:00 a.m.</p>  | <p><b>Welcome to Day 2 from CCRAN’s President &amp; CEO</b></p> <p>A warm welcome and sincere thanks to all experts and participants. Key highlights in this session:</p> <ul style="list-style-type: none"> <li>• A patient perspective, sharing their cancer journey</li> <li>• Exploring patient insights to help advance meaningful cancer care</li> </ul>   | <p><b>Filomena Servidio-Italiano, Hon B.Sc., B.Ed., M.A.</b><br/>President &amp; CEO, CCRAN</p> <p><u>Patient Perspective</u><br/><b>Michelle Audoin</b><br/>Chair, Patient Representative Committee, Canadian Cancer Trials Group (CCTG); Patient Advocate and Community Collaborator; All.Can Canada Evidence Working Group; Stage IV Breast Cancer and Thyroid Cancer Patient</p>  |
| <p>10:00 a.m. – 11:30 a.m.</p> | <p><b>A National Conversation on CGP Becoming a Standard of Care</b></p> <p>As provinces across Canada work to advance access to comprehensive genomic profiling (CGP), clinical teams are navigating varying system conditions, infrastructure, and expectations. This national roundtable will bring together frontline clinicians to build clinical consensus that CGP <i>should</i> be established as a standard of care, and to identify the conditions needed to support equitable, informed clinical decision-making across Canada.</p> <p>Panelists will reflect on their jurisdictional contexts, identifying shared challenges and enablers related to team capacity, informatics, turnaround times, and lab resources. Rather than prescribing a uniform approach, the session will focus on identifying where alignment is most needed, across care settings, provinces, and specialties, to advance CGP in a way that is both scalable and responsive to local needs.</p> <p>Key objectives:</p> <ul style="list-style-type: none"> <li>• Frame CGP as a standard of care across tumour types and jurisdictions, grounded in clinical experience and evolving evidence</li> <li>• Define the key system requirements needed to support CGP informed care, including infrastructure and clinical workflows</li> <li>• Identify priority areas for clinical alignment in practice, referral pathways, and decision-making across provinces</li> </ul> | <p><u>Moderator</u><br/><b>Dr. Monika Krzyzanowska, MD, MPH, FRCPC, FASCO</b><br/>Co-Chair, Expert Steering Committee; Chief &amp; Medical Oncologist, Odette Cancer Centre, Sunnybrook Health Sciences Centre; Regional Vice President, Ontario Health (Cancer Care Ontario); Professor of Medicine, University of Toronto</p> <p><u>Caregiver Perspective</u><br/><b>Neil Marr, Hon B.A.</b><br/>Caregiver to spouse who succumbed to Stage IV Cholangiocarcinoma; Research Advocate and Mentor; Patient Partner with PanCuRx</p> <p><u>Clinician Roundtable</u><br/><b>Dr. Mita Manna, MD, FRCPC</b><br/>Medical Oncologist, Saskatoon Cancer Centre; Associate Professor, Department of Oncology, University of Saskatchewan</p> <p><b>Dr. Stephanie Snow, MD, FRCPC</b><br/>Medical Oncologist, QEII Health Sciences Centre; Professor, Dalhousie University</p> |

|                         |  |   |
|-------------------------|--|---|
|                         |  | <p><b>Dr. Rebecca Auer, MD, M.Sc., FRCSC, FACS</b><br/>Executive Vice-President, Research &amp; Innovation, The Ottawa Hospital; CEO &amp; Scientific Director, Ottawa Hospital Research Institute; Professor, Departments of Surgery, Biochemistry, Immunology &amp; Microbiology, University of Ottawa</p> <p><b>Dr. Shantanu Banerji, B.Sc. (Med), MD, FRCPC</b><br/>Co-Chair, Expert Steering Committee; Director of Precision Oncology and Advanced Therapeutics, CancerCare Manitoba</p> <p><b>Dr. Yoo-Joung Ko, MD, MMS, M.Sc.</b><br/>Medical Oncologist, St. Michael's Hospital, Unity Health; Medical Director, Cancer &amp; Endoscopy Program, Unity Health</p> <p><b>Dr. Urban Emmenegger, MD</b><br/>Medical Oncologist, Odette Cancer Centre, Sunnybrook Health Sciences Centre; Associate Professor, Department of Medicine, University of Toronto</p> <p><b>Dr. Jason Karamchandani, MD</b><br/>Associate Professor, Departments of Pathology, Neurology and Neurosurgery, McGill University; President, Canadian Association of Pathologists</p> |
| 11:30 a.m. – 12:15 p.m. | <p style="text-align: center;"><b>Health Break</b></p> <p style="text-align: center;">Featured Video: <a href="#">Second Look Cancer - Clinical Trial Matching Tool</a></p> <p style="text-align: center;">Dillan Eisenhaur, Founder</p> |   |

|                               |   |   |
|-------------------------------|---|---|
| <p>12:15 p.m. – 1:30 p.m.</p> | <p><b>Unlocking the Research Pipeline: Bridging Clinical Trials and Real-World Genomics</b></p> <p>As comprehensive genomic profiling (CGP) moves toward standard of care, the ability to translate genomic data into actionable evidence becomes increasingly critical. This session examines how real-world CGP data and coordinated genomic infrastructure can strengthen Canada’s research ecosystem, particularly where traditional trial evidence is limited. By focusing on data integration, evidence generation, and national coordination, the discussion will consider how genomics can better inform research, regulatory, and system-level decision-making, and support a more connected, pan-Canadian approach to precision oncology innovation.</p> <p>This session will explore:</p> <ul style="list-style-type: none"> <li>• Persistent gaps in clinical trial inclusion for metastatic cancer patients eligible for CGP, and how these gaps impact innovation and access</li> <li>• The role of real-world genomic data, including CGP, whole genome sequencing, and other advanced molecular diagnostics, in informing drug development, regulatory decision-making, and health technology assessment</li> <li>• Collaborative research models that integrate CGP into clinical and translational studies</li> <li>• How national genomic repositories and data-sharing platforms can support a more coordinated, pan-Canadian research and innovation strategy</li> </ul> | <p><u>Moderator</u><br/> <b>Dr. Stéphanie Michaud, Ph.D.</b><br/> President and CEO, BioCanRx</p> <p><u>Patient Perspective</u><br/> <b>Dillan Eisenhaur</b><br/> Stage IV Colorectal Cancer Patient; Founder, Second Look Cancer Inc.</p> <p><u>Panelists</u><br/> <b>Dr. Yvonne Bombard, Ph.D.</b><br/> Canada Research Chair, Genomics Health Services &amp; Policy; Professor, University of Toronto; Director &amp; Scientist, St. Michael's Hospital; Co-Founder &amp; CEO, Genetics Adviser</p> <p><b>Dr. Jim Woodgett</b><br/> President and Scientific Director, The Terry Fox Research Institute (TFRI)</p> <p><b>Dr. Arvind N. Dasari, MD</b><br/> Director of Clinical Research, Dept. of GI Medical Oncology, University of Texas MD Anderson Cancer Center, USA</p> |
| <p>1:30 p.m. – 3:00 p.m.</p>  | <p><b>Patient Group Reflections on the Case for CGP Investment</b></p> <p>As health systems across Canada consider the integration of CGP into standard cancer care, patient groups play a critical role in highlighting access gaps and articulating priorities for investment. This roundtable brings together patient organizations from across tumour types to reflect on their experiences advocating for CGP within diverse health system contexts. The discussion will explore how patient groups identify unmet needs, coordinate advocacy efforts, and define what meaningful CGP investment looks like from a patient and community perspective.</p>  | <p><u>Moderator</u><br/> <b>Filomena Servidio-Italiano, Hon B.Sc., B.Ed., M.A.</b><br/> President &amp; CEO, CCRAN</p> <p><u>Patient Group Roundtable</u><br/> <b>Ayelet Borgida, M.Sc.</b><br/> Director of Medical and Health Initiatives, Pancreatic Cancer North America</p>  |

|                       |   |   |
|-----------------------|---|---|
|                       | <p>The discussion will also include early reflections on CCRAN’s CGP Phase II Research Initiative, focusing on how real-world evidence can help inform future decision-making and support more consistent implementation of CGP across Canada.</p> <p>Speakers will elaborate on the following topics:</p> <ul style="list-style-type: none"> <li>• The role of real-world evidence in informing CGP implementation</li> <li>• How patient groups are engaging stakeholders to shape priorities and inform decision-making</li> <li>• Barriers to achieving consistent access and standardization of CGP testing across jurisdictions</li> <li>• Strategic approaches to strengthen advocacy impact across jurisdictions</li> </ul> | <p><b>Lindsay Timm</b><br/>Executive Director, Canadian Cancer Survivor Network (CCSN)</p> <p><b>Winky Yau</b><br/>Manager, Medical Affairs, Lung Cancer Canada</p> <p><b>Teresa Norris</b><br/>Sexual Health Specialist; Founder &amp; President, HPV Global Action</p> <p><b>JK Miller</b><br/>Health Policy &amp; Advocacy Lead, Canadian Breast Cancer Network</p> <p><b>Laz Bouros</b><br/>President, Thyroid Foundation of Canada</p> <p><b>Austin Zimmer, B.Sc., M.Sc.</b><br/>Support Services Manager &amp; Research Coordinator, Prostate Cancer Foundation Canada</p> <p><b>Shannon Phillips</b><br/>Board Member, My Gut Feeling, Stomach Cancer Foundation of Canada</p> |
| 3:00 p.m. – 3:15 p.m. | <p><b>Health Break</b></p> <p><b>Educational Videos</b></p>   |   |
| 3:15 p.m. – 4:15 p.m. | <p><b>Scaling What Matters: Building on Economic Evidence to Help Inform Policy</b></p> <p>As Canada progresses toward a more aligned approach to comprehensive genomic profiling (CGP) in metastatic cancer care, economic evidence is emerging as a central lever for advancing shared understanding across clinical, policy, and patient communities. This session will explore how the cost and benefit findings can clarify the value of CGP from multiple vantage points and support a more</p>   | <p><i>Moderator</i></p> <p><b>Dr. Étienne Richer, Ph.D.</b><br/>Director of Genomics Programs, Genome Canada</p>  |

|                              |   |  |
|------------------------------|---|--|
|                              | <p>coordinated national dialogue. Panelists will reflect on how economic insights can be translated into strategic, scalable insights to inform future system planning. The discussion will emphasize where stakeholder priorities converge and how economic considerations can be used to inform coordinated CGP planning across provinces.</p> <p>Guiding objectives include:</p> <ul style="list-style-type: none"> <li>• Highlighting key takeaways from CCRAN’s CGP initiative, including economic and real-world evidence, and how they inform next-stage decision-making</li> <li>• Engaging multi-stakeholder voices in discussing what is needed to support this transition from research to national alignment</li> <li>• Demonstrating how collaborative models can support the system-wide adoption and integration of CGP across Canada, ensuring readiness for scale-up in clinical, policy, and operational domains</li> </ul> | <p><u>Patient Perspective</u><br/> <b>Steve Slack</b><br/> Stage IV Colon Cancer Survivor</p> <p><u>Panelists</u><br/> <b>Eddy Nason, MPhil, B.Sc.</b><br/> Director, Health, Signal49 Research</p> <p><b>Matthew Brougham</b><br/> Senior Global Consultant, Certara Evidence &amp; Access;<br/> President &amp; CEO, Brougham Consulting Inc.</p> <p><b>Dr. Sandeep Sehdev, MD, FRCPC</b><br/> Medical Oncologist &amp; Assistant Professor, The Ottawa Hospital Cancer Centre; Associate Professor of Medicine, University of Ottawa</p> <p><b>Dr. Sandeep Sehdev, MD, FRCPC</b><br/> Medical Oncologist, The Ottawa Hospital Cancer Centre;<br/> Associate Professor of Medicine, University of Ottawa</p> |
| <p>4:15 p.m. – 5:15 p.m.</p> | <p><b>From Laboratory Readiness to Patient Impact: Why CGP Falls Short and What Must Change</b></p> <p>While comprehensive genomic profiling (CGP) remains a central focus in metastatic cancer care, broader genomic technologies, including whole genome sequencing and other advanced molecular diagnostics, are increasingly shaping precision oncology infrastructure requirements. As CGP demonstrates clear clinical and economic value, persistent implementation barriers continue to limit its consistent funding and delivery across Canada.</p> <p>While many centres have developed strong genomic capabilities, implementation remains variable across jurisdictions. This session examines the most pressing constraints preventing CGP and related advanced genomic testing from becoming routine practice, with a particular focus on laboratory capacity, diagnostic workflows, and system readiness conditions.</p>        | <p><u>Moderator</u><br/> <b>Andrea Tjahja, MLT, ART, B.Sc., B.Ed.</b><br/> Vice President, Operations, Medical Laboratory Professionals' Association of Ontario (MLPAO)</p> <p><u>Patient Perspective</u><br/> <b>TBD</b></p> <p><u>Panelists</u><br/> <b>Craig Ivany, B. Comm, MBA, CHE, ICD.D</b><br/> Adjunct Professor, Pathology and Laboratory Medicine, University of British Columbia</p>  |

|                       |  |  |
|-----------------------|--|--|
|                       | <p>The discussion connects system-level barriers, such as variable testing criteria, turnaround times, and fragmented diagnostic pathways, to their broader impact on patient care. The session will examine how these system constraints affect the timing and quality of treatment decision-making within cancer care. By examining system and policy considerations through a real-world patient lens, the session aims to clarify where breakdowns occur and what is required to move CGP and advanced genomic testing from inconsistent access to sustained, reliable integration within routine cancer care.</p> <p>This multi-disciplinary panel will explore:</p> <ul style="list-style-type: none"> <li>• Key laboratory, diagnostic, and system-level barriers limiting the consistent implementation of CGP and other advanced genomic testing across Canada</li> <li>• Health system and workforce considerations, including laboratory capacity, health human resources, and interprofessional collaboration required to support scalable genomic testing</li> <li>• Practical readiness conditions and system enablers needed to support the routine, accountable integration of CGP into cancer care</li> </ul> | <p><b>Andrea Beharry</b><br/>Manager, Clinical Services, Advanced Diagnostics, William Osler Health System</p> <p><b>Dr. Jason Karamchandani, MD</b><br/>Associate Professor, Departments of Pathology, Neurology and Neurosurgery, McGill University;<br/>President, Canadian Association of Pathologists</p> <p><b>Prof. Brenda Gamble, Ph.D.</b><br/>Associate Professor, Faculty of Health Sciences and Program Director, Bachelor of Health Administration &amp; Allied Health Sciences, Ontario Tech University</p> <p><i>Additional experts to be confirmed</i></p> |
| 5:15 p.m. – 5:30 p.m. | <b>Day 2 Closing Remarks and Conference Adjournment.</b>   | <b>Filomena Servidio-Italiano, Hon B.Sc., B.Ed., M.A.</b><br>President & CEO, CCRAN  |